ST. LOUIS, Mo.--Tripos, a molecular informatics, design, and analysis company here, has acquired Receptor Research, a specialty chemistry company based in Bude, Cornwall. The purchase allows Tripos to directly apply its expertise in new compound discovery collaborations in the pharmaceutical, biotechnology, agrochemical, and related industries, according to the company.
"We are extremely pleased to add Receptor Research to our operations," commented John McAlister, Tripos's president and CEO. "Their sterling reputation for creativity and high-quality, novel chemical synthesis complements that of Tripos for informatics and service among our customers. Working with Receptor and investing to significantly expand its laboratory operations, we will bring unprecedented capability to lead discovery and optimization partnerships." He concluded by saying the purchase will further the chemoinformatics company's goal of becoming a broad-based, international discovery partner to the pharmaceutical and related industries. The purchase is also a good fit with Tripos's recent investments in Arena Pharmaceuticals, a receptor identification, biology, and screening company, and Phase-1, a molecular toxicology screening company, McAlister stated.
As a result of the acquisition, Receptor will change its name to Tripos Receptor Research and hire additional staffers--including chemists and robotics experts--at its headquarters.